Idera Pharmaceuticals (NASDAQ:IDRA) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the superior ...
Feeds
37388 items (37388 unread) in 74 feeds
Acinar Cell Carcinoma
(249 unread)
Acinic Cell Carcinoma
(163 unread)
Adenoid Cystic Carcinoma
(812 unread)
Adrenal Gland Cancer
(3080 unread)
Ampulla Of Vater
(1026 unread)
Anal Cancer
(3839 unread)
Angiosarcoma
(1177 unread)
Appendix Cancer
(509 unread)
Bile Duct Cancer
(4510 unread)
Brain and CNS
(4965 unread)
Carcinoid
(1597 unread)
Endocrine/Neuroendocrine
(4186 unread)
Gall Bladder Cancer
(1686 unread)
Hemangioendothelioma
(424 unread)
Hepatoblastoma
(568 unread)
Pancreas
(505 unread)
Phyllodes
(290 unread)
PMP and Mucinous Tumors
(360 unread)
Rhabdomyosarcoma
(1361 unread)
Sarcoma
(6081 unread)
Google - Angiosarcoma (100 unread)
-
Idera Pharmaceuticals (NASDAQ:IDRA) vs. TRACON Pharmaceuticals (NASDAQ:TCON) Head-To-Head Contrast - Mayfield Recorder
Posted: August 18th, 2019, 2:45am GMT
Idera Pharmaceuticals (NASDAQ:IDRA) vs. TRACON Pharmaceuticals (NASDAQ:TCON) Head-To-Head Contrast Mayfield Recorder -
Zacks Investment Research Downgrades TRACON Pharmaceuticals (NASDAQ:TCON) to Sell - Sundance Herald
Posted: August 17th, 2019, 9:28am GMT
Zacks Investment Research Downgrades TRACON Pharmaceuticals (NASDAQ:TCON) to Sell Sundance HeraldTRACON Pharmaceuticals (NASDAQ:TCON) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to ...
-
Athenex, Inc. (ATNX) Reaches $15.47 After 9.00% Up Move; Bridgewater Associates LP Lowered Open Text (OTEX) Position - The EN Herald
Posted: August 16th, 2019, 2:44pm GMT
Athenex, Inc. (ATNX) Reaches $15.47 After 9.00% Up Move; Bridgewater Associates LP Lowered Open Text (OTEX) Position The EN HeraldBridgewater Associates Lp decreased Open Text Corp (OTEX) stake by 23.98% reported in 2019Q1 SEC filing. Bridgewater Associates Lp sold 20,028 shares ...
-
TRACON Pharmaceuticals (NASDAQ:TCON) Issues Earnings Results, Misses Expectations By $0.02 EPS - Sundance Herald
Posted: August 16th, 2019, 1:02pm GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Issues Earnings Results, Misses Expectations By $0.02 EPS Sundance HeraldTRACON Pharmaceuticals (NASDAQ:TCON) issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.21) ...
-
TRACON Pharmaceuticals (NASDAQ:TCON) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - Riverton Roll
Posted: August 16th, 2019, 12:20pm GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS Riverton RollTRACON Pharmaceuticals (NASDAQ:TCON) issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.21) ...
-
TRACON Pharmaceuticals Inc. (TCON) and Catalyst Biosciences Inc. (NASDAQ:CBIO) Contrasting side by side - Stocks Beat
Posted: August 16th, 2019, 11:53pm GMT
TRACON Pharmaceuticals Inc. (TCON) and Catalyst Biosciences Inc. (NASDAQ:CBIO) Contrasting side by side Stocks BeatAs Biotechnology businesses, TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Catalyst Biosciences Inc. (NASDAQ:CBIO), are affected by compare.
-
TRACON Pharmaceuticals Inc. (TCON) and Urovant Sciences Ltd. (NASDAQ:UROV) Comparing side by side - Stocks Beat
Posted: August 15th, 2019, 3:57pm GMT
TRACON Pharmaceuticals Inc. (TCON) and Urovant Sciences Ltd. (NASDAQ:UROV) Comparing side by side Stocks BeatWe will be contrasting the differences between TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Urovant Sciences Ltd. (NASDAQ:UROV) as far as ...
-
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Oragenics Inc. (NYSEAMERICAN:OGEN)'s results - Stocks Beat
Posted: August 15th, 2019, 11:39pm GMT
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Oragenics Inc. (NYSEAMERICAN:OGEN)'s results Stocks BeatTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Oragenics Inc. (NYSEAMERICAN:OGEN) have been rivals in the Biotechnology for quite some time.
-
Athenex, Inc. (ATNX) Reaches $15.07 After 5.00% Up Move; Crescent Park Management LP Has Trimmed Td Ameritrade Hldg (AMTD) Stake - Stocks Beat
Posted: August 14th, 2019, 1:32pm GMT
Athenex, Inc. (ATNX) Reaches $15.07 After 5.00% Up Move; Crescent Park Management LP Has Trimmed Td Ameritrade Hldg (AMTD) Stake Stocks BeatThe stock of Athenex, Inc. (NASDAQ:ATNX) is a huge mover today! The stock increased 1.79% or $0.26 during the last trading session, reaching $15.07.
-
Charles Theuer Purchases 50,000 Shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock - Mayfield Recorder
Posted: August 14th, 2019, 12:51pm GMT
Charles Theuer Purchases 50,000 Shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock Mayfield RecorderTRACON Pharmaceuticals Inc (NASDAQ:TCON) insider Charles Theuer purchased 50000 shares of TRACON Pharmaceuticals stock in a transaction on Friday, ...
-
Charles Theuer Purchases 50,000 Shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock - Riverton Roll
Posted: August 14th, 2019, 12:50pm GMT
Charles Theuer Purchases 50,000 Shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock Riverton RollTRACON Pharmaceuticals Inc (NASDAQ:TCON) insider Charles Theuer purchased 50000 shares of the company's stock in a transaction that occurred on ...
-
What Will Happen to Tracon Pharmaceuticals Inc (NASDAQ:TCON) Next? The Stock Has Decline in Shorts - The MAK Daily
Posted: August 13th, 2019, 2:23pm GMT
What Will Happen to Tracon Pharmaceuticals Inc (NASDAQ:TCON) Next? The Stock Has Decline in Shorts The MAK DailyThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered a decrease of 9.01% in short interest. TCON's total short interest was 694600 shares in.
-
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Insider Charles Theuer Buys 50,000 Shares - Tech Know Bits
Posted: August 13th, 2019, 8:35am GMT
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Insider Charles Theuer Buys 50,000 Shares Tech Know BitsTRACON Pharmaceuticals Inc (NASDAQ:TCON) insider Charles Theuer purchased 50000 shares of TRACON Pharmaceuticals stock in a transaction dated ...
-
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Insider Charles Theuer Buys 50,000 Shares - Sundance Herald
Posted: August 13th, 2019, 8:33am GMT
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Insider Charles Theuer Buys 50,000 Shares Sundance HeraldTRACON Pharmaceuticals Inc (NASDAQ:TCON) insider Charles Theuer purchased 50000 shares of TRACON Pharmaceuticals stock in a transaction dated ...
-
Angiosarcomas Treatment Market 2026 Application, Consumption, Market Share, Growth Opportunities, Regions - Business Intelligence
Posted: August 13th, 2019, 4:29am GMT
Angiosarcomas Treatment Market 2026 Application, Consumption, Market Share, Growth Opportunities, Regions Business IntelligenceAngiosarcoma is a rare cancer of the inner lining of blood vessels, which occur in any area of the body, including the skin, breast, liver, spleen, and deep tissue ...
-
Head-To-Head Review: Idera Pharmaceuticals (NASDAQ:IDRA) vs. TRACON Pharmaceuticals (NASDAQ:TCON) - Tech Know Bits
Posted: August 12th, 2019, 11:39am GMT
Head-To-Head Review: Idera Pharmaceuticals (NASDAQ:IDRA) vs. TRACON Pharmaceuticals (NASDAQ:TCON) Tech Know BitsIdera Pharmaceuticals (NASDAQ:IDRA) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the better ...
-
Angiosarcomas Treatment Market Upcoming Demand & Growth Analysis Up to 2026 - Coherent Magazine
Posted: August 12th, 2019, 12:50am GMT
Angiosarcomas Treatment Market Upcoming Demand & Growth Analysis Up to 2026 Coherent MagazineThe Angiosarcomas Treatment Market research report gives details about the Angiosarcomas Treatment market, its size, segments, financial growth, products, ...
-
Athenex, Inc. (ATNX) Reaches $14.32 After 6.00% Down Move; KANSAI PAINT F ORDINARY SHARES (KSANF) Shorts Lowered By 3.36% - The EN Herald
Posted: August 11th, 2019, 2:09pm GMT
Athenex, Inc. (ATNX) Reaches $14.32 After 6.00% Down Move; KANSAI PAINT F ORDINARY SHARES (KSANF) Shorts Lowered By 3.36% The EN HeraldThe stock of Athenex, Inc. (NASDAQ:ATNX) is a huge mover today! The stock decreased 7.01% or $1.08 during the last trading session, reaching $14.32.
-
What Will Happen to TRACON Pharmaceuticals, Inc. (TCON) Next? The Stock Just Reaches All-Time Low - The MAK Daily
Posted: August 11th, 2019, 1:14pm GMT
What Will Happen to TRACON Pharmaceuticals, Inc. (TCON) Next? The Stock Just Reaches All-Time Low The MAK DailyThe stock of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) reached all time low today, Aug, 11 and still has $0.43 target or 4.00 % below today's $0.45 share ...
-
Could TRACON Pharmaceuticals, Inc. (TCON) Go Up After Making All-Time Low? - The Altcoin Mercury
Posted: August 11th, 2019, 1:14pm GMT
Could TRACON Pharmaceuticals, Inc. (TCON) Go Up After Making All-Time Low? The Altcoin MercuryThe stock of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) reached all time low today, Aug, 11 and still has $0.43 target or 4.00 % below today's $0.45 share ...
-
What's TRACON Pharmaceuticals, Inc. (TCON) Downside After Achieving Yearly Low? - The MAK Daily
Posted: August 10th, 2019, 2:35pm GMT
What's TRACON Pharmaceuticals, Inc. (TCON) Downside After Achieving Yearly Low? The MAK DailyThe stock of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) hit a new 52-week low and has $0.43 target or 4.00 % below today's $0.45 share price.
-
What's TRACON Pharmaceuticals, Inc. (TCON) Downside After Achieving Yearly Low? - The MAK Daily
Posted: August 10th, 2019, 2:35pm GMT
What's TRACON Pharmaceuticals, Inc. (TCON) Downside After Achieving Yearly Low? The MAK DailyThe stock of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) hit a new 52-week low and has $0.43 target or 4.00 % below today's $0.45 share price.
-
New Hope for Advanced Sarcomas - Cancer Network
Posted: August 9th, 2019, 8:31pm GMT
New Hope for Advanced Sarcomas Cancer NetworkNew hope for advanced sarcomas. Naveed Saleh, MD, MS. Apatinib treatment demonstrated objective efficacy in advanced sarcoma patients, according to the ...
-
TRACON Pharmaceuticals, Inc. (TCON) Stock Is At All-Time Low Now - The MAK Daily
Posted: August 9th, 2019, 1:16pm GMT
TRACON Pharmaceuticals, Inc. (TCON) Stock Is At All-Time Low Now The MAK DailyThe stock of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) reached all time low today, Aug, 9 and still has $0.39 target or 7.00 % below today's $0.42 share.
-
TRACON Pharmaceuticals (NASDAQ:TCON) Announces Earnings Results - Sundance Herald
Posted: August 9th, 2019, 12:40pm GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Announces Earnings Results Sundance HeraldTRACON Pharmaceuticals (NASDAQ:TCON) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.21) EPS for the quarter ...
-
TRACON Pharmaceuticals (NASDAQ:TCON) Announces Earnings Results - Riverton Roll
Posted: August 9th, 2019, 11:56am GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Announces Earnings Results Riverton RollTRACON Pharmaceuticals (NASDAQ:TCON) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.21) EPS for the quarter ...
-
Edited Transcript of ATNX earnings conference call or presentation 7-Aug-19 12:00pm GMT - Yahoo Finance
Posted: August 8th, 2019, 8:19pm GMT
Edited Transcript of ATNX earnings conference call or presentation 7-Aug-19 12:00pm GMT Yahoo FinanceQ2 2019 Athenex Inc Earnings Call. BUFFALO Aug 8, 2019 (Thomson StreetEvents) -- Edited Transcript of Athenex Inc earnings conference call or presentation ...
-
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Reports Decline in Sellers; Strong Momentum for Longs - The MAK Daily
Posted: August 8th, 2019, 1:34pm GMT
Tracon Pharmaceuticals Inc (NASDAQ:TCON) Reports Decline in Sellers; Strong Momentum for Longs The MAK DailyThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered a decrease of 9.01% in short interest. TCON's total short interest was 694600 shares in.
-
Will Tracon Pharmaceuticals Inc (NASDAQ:TCON) Run Out of Steam Soon? Short Interest Is Down - Invest Tribune
Posted: August 8th, 2019, 1:19pm GMT
Will Tracon Pharmaceuticals Inc (NASDAQ:TCON) Run Out of Steam Soon? Short Interest Is Down Invest TribuneThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered a decrease of 9.01% in short interest. TCON's total short interest was 694600 shares in.
-
Athenex Announces Oral Paclitaxel And Encequidar Had A Significantly Higher Response Rate Over IV Paclitaxel In A Phase III Pivotal Study In Metastatic Breast Cancer - Clinical Leader
Posted: August 8th, 2019, 3:02am GMT
Athenex Announces Oral Paclitaxel And Encequidar Had A Significantly Higher Response Rate Over IV Paclitaxel In A Phase III Pivotal Study In Metastatic Breast Cancer Clinical LeaderStudy met primary endpoint showing statistically significant improvement in overall response rate for oral paclitaxel and encequidar (Oral Paclitaxel) compared ...
-
TRACON Pharmaceuticals, Inc. (TCON) EPS Estimated At $-0.19 - Invest Tribune
Posted: August 7th, 2019, 3:26pm GMT
TRACON Pharmaceuticals, Inc. (TCON) EPS Estimated At $-0.19 Invest TribuneAnalysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
-
Analysts See $-0.44 EPS for Athenex, Inc. (ATNX); Guardian Capital Advisors LP Decreased Westpac Bkg (WBK) Stake By $2.05 Million - The EN Herald
Posted: August 7th, 2019, 12:25pm GMT
Analysts See $-0.44 EPS for Athenex, Inc. (ATNX); Guardian Capital Advisors LP Decreased Westpac Bkg (WBK) Stake By $2.05 Million The EN HeraldAnalysts expect Athenex, Inc. (NASDAQ:ATNX) to report $-0.44 EPS on August, 13.They anticipate $0.14 EPS change or 24.14% from last quarter's $-0.58 EPS.
-
Global orphan drugs market is projected to reach $169 billion from $106 billion and register a CAGR of 6.8% by 2022 - Trading Herald
Posted: August 7th, 2019, 10:56am GMT
Global orphan drugs market is projected to reach $169 billion from $106 billion and register a CAGR of 6.8% by 2022 Trading HeraldThe Global orphan drugs market was valued at $106 billion in 2015, and is projected to reach $169 billion by 2022, growing at a CAGR of 6.8% from 2016 to ...
-
Head to Head Survey: Gene Biotherapeutics (OTCMKTS:CRXM) vs. TRACON Pharmaceuticals (OTCMKTS:TCON) - Mayfield Recorder
Posted: August 7th, 2019, 10:01am GMT
Head to Head Survey: Gene Biotherapeutics (OTCMKTS:CRXM) vs. TRACON Pharmaceuticals (OTCMKTS:TCON) Mayfield RecorderGene Biotherapeutics (OTCMKTS:CRXM) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the better ...
-
Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel - EIN News
Posted: August 7th, 2019, 8:35am GMT
Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel EIN NewsPositive Phase III results of Oral Paclitaxel show statistically significant improvement in overall response rate in metastatic breast cancer Company is.
-
Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel - EIN News
Posted: August 7th, 2019, 8:35am GMT
Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel EIN NewsPositive Phase III results of Oral Paclitaxel show statistically significant improvement in overall response rate in metastatic breast cancer Company is.
-
Form 8-K Athenex, Inc. For: Aug 07 - StreetInsider.com
Posted: August 7th, 2019, 8:33am GMT
Form 8-K Athenex, Inc. For: Aug 07 StreetInsider.com(Exact name of registrant as specified in its charter). Delaware, 001-38112, 43-1985966. (State or other jurisdiction. of incorporation). (Commission. File Number).
-
Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer - Yahoo Finance
Posted: August 7th, 2019, 8:00am GMT
Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer Yahoo FinanceStudy met primary endpoint showing statistically significant improvement in overall response rate for oral paclitaxel and encequidar (Oral Paclitaxel) compared ...
-
Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer - Yahoo Finance
Posted: August 7th, 2019, 8:00am GMT
Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer Yahoo FinanceStudy met primary endpoint showing statistically significant improvement in overall response rate for oral paclitaxel and encequidar (Oral Paclitaxel) compared ...
-
Reviewing Neuralstem Inc. (CUR)'s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)'s results - Stocks Beat
Posted: August 7th, 2019, 11:28pm GMT
Reviewing Neuralstem Inc. (CUR)'s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)'s results Stocks BeatThis is therefore a contrasting of the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation in Neuralstem Inc.
-
What's Propelling Athenex, Inc. (ATNX) to Increase So Much? - The MAK Daily
Posted: August 6th, 2019, 6:31pm GMT
What's Propelling Athenex, Inc. (ATNX) to Increase So Much? The MAK DailyThe stock of Athenex, Inc. (NASDAQ:ATNX) is a huge mover today! The stock increased 5.56% or $1 during the last trading session, reaching $18.97.
-
What's Propelling Athenex, Inc. (ATNX) to Increase So Much? - The MAK Daily
Posted: August 6th, 2019, 6:31pm GMT
What's Propelling Athenex, Inc. (ATNX) to Increase So Much? The MAK DailyThe stock of Athenex, Inc. (NASDAQ:ATNX) is a huge mover today! The stock increased 5.56% or $1 during the last trading session, reaching $18.97.
-
Analysts See $-0.44 EPS for Athenex, Inc. (ATNX); KOBAYASHI PHARMACEUTICAL CO LTD OSAKA OR (KBYPF) Shorts Raised By 13.16% - Stocks Beat
Posted: August 6th, 2019, 9:37am GMT
Analysts See $-0.44 EPS for Athenex, Inc. (ATNX); KOBAYASHI PHARMACEUTICAL CO LTD OSAKA OR (KBYPF) Shorts Raised By 13.16% Stocks BeatAnalysts expect Athenex, Inc. (NASDAQ:ATNX) to report $-0.44 EPS on August, 13.They anticipate $0.14 EPS change or 24.14% from last quarter's $-0.58 EPS.
-
Comparing of TRACON Pharmaceuticals Inc. (TCON) and Evofem Biosciences Inc. (NASDAQ:EVFM) - The EN Herald
Posted: August 6th, 2019, 6:06am GMT
Comparing of TRACON Pharmaceuticals Inc. (TCON) and Evofem Biosciences Inc. (NASDAQ:EVFM) The EN HeraldWe are contrasting TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Evofem Biosciences Inc. (NASDAQ:EVFM) on their profitability, analyst ...
-
TRACON Pharmaceuticals, Inc. (TCON) Analysts See $-0.19 EPS - Invest Tribune
Posted: August 6th, 2019, 5:00am GMT
TRACON Pharmaceuticals, Inc. (TCON) Analysts See $-0.19 EPS Invest TribuneAnalysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
-
TRACON Pharmaceuticals Inc. (TCON) and IDEAYA Biosciences Inc. (NASDAQ:IDYA) Comparing side by side - CryptoCoinsTribune
Posted: August 6th, 2019, 4:58am GMT
TRACON Pharmaceuticals Inc. (TCON) and IDEAYA Biosciences Inc. (NASDAQ:IDYA) Comparing side by side CryptoCoinsTribuneBoth TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and IDEAYA Biosciences Inc. (NASDAQ:IDYA) are Biotechnology companies, competing one another.
-
$-0.44 EPS Expected for Athenex, Inc. (ATNX); One Gas (OGS) Sentiment Is 1.44 - The InvestReporter
Posted: August 5th, 2019, 10:07am GMT
$-0.44 EPS Expected for Athenex, Inc. (ATNX); One Gas (OGS) Sentiment Is 1.44 The InvestReporterOne Gas Inc (OGS) investors sentiment increased to 1.44 in 2019 Q1. It's up 0.37, from 1.07 in 2018Q4. The ratio increased, as 128 investment managers ...
-
Comparison of TRACON Pharmaceuticals Inc. (TCON) and VBI Vaccines Inc. (NASDAQ:VBIV) - The InvestReporter
Posted: August 5th, 2019, 7:49am GMT
Comparison of TRACON Pharmaceuticals Inc. (TCON) and VBI Vaccines Inc. (NASDAQ:VBIV) The InvestReporterThis is a contrast between TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and VBI Vaccines Inc. (NASDAQ:VBIV) based on their institutional ownership, ...
-
Angiosarcomas Treatment Market Industry Growth, Size, Share, Opportunity, and Analysis | 2018-2026 - Veterans Insights
Posted: August 5th, 2019, 12:51am GMT
Angiosarcomas Treatment Market Industry Growth, Size, Share, Opportunity, and Analysis | 2018-2026 Veterans InsightsAngiosarcomas Treatment market reports provides a comprehensive overview of the global market size and share. Angiosarcomas Treatment market data ...
-
TRACON Pharmaceuticals Inc. (TCON)'s Financial Results Comparing With Stoke Therapeutics Inc. (NASDAQ:STOK) - The InvestReporter
Posted: August 5th, 2019, 12:09am GMT
TRACON Pharmaceuticals Inc. (TCON)'s Financial Results Comparing With Stoke Therapeutics Inc. (NASDAQ:STOK) The InvestReporterBoth TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Stoke Therapeutics Inc. (NASDAQ:STOK) are each other's competitor in the Biotechnology industry.
-
LogicBio Therapeutics Inc. (LOGC) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Comparing side by side - Stocks Beat
Posted: August 3rd, 2019, 10:02am GMT
LogicBio Therapeutics Inc. (LOGC) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Comparing side by side Stocks BeatWe are contrasting LogicBio Therapeutics Inc. (NASDAQ:LOGC) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) on their analyst recommendations, ...
-
TRACON Pharmaceuticals Inc. (TCON) and Citius Pharmaceuticals Inc. (NASDAQ:CTXR) Comparing side by side - Stocks Beat
Posted: August 3rd, 2019, 11:44pm GMT
TRACON Pharmaceuticals Inc. (TCON) and Citius Pharmaceuticals Inc. (NASDAQ:CTXR) Comparing side by side Stocks BeatTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Citius Pharmaceuticals Inc. (NASDAQ:CTXR), are influenced by compare since they are both players in ...
-
Analysts See $-0.44 EPS for Athenex, Inc. (ATNX); RF Industries LTD (RFIL) Has 0.93 Sentiment - The NBO News
Posted: August 2nd, 2019, 1:46pm GMT
Analysts See $-0.44 EPS for Athenex, Inc. (ATNX); RF Industries LTD (RFIL) Has 0.93 Sentiment The NBO NewsAnalysts expect Athenex, Inc. (NASDAQ:ATNX) to report $-0.44 EPS on August, 13.They anticipate $0.14 EPS change or 24.14% from last quarter's $-0.58 EPS.
-
Analysts See $-0.19 EPS for TRACON Pharmaceuticals, Inc. (TCON) - The MAK Daily
Posted: August 2nd, 2019, 11:08pm GMT
Analysts See $-0.19 EPS for TRACON Pharmaceuticals, Inc. (TCON) The MAK DailyAnalysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
-
TRACON Pharmaceuticals, Inc. (TCON) EPS Estimated At $-0.19 - Invest Tribune
Posted: August 2nd, 2019, 10:57pm GMT
TRACON Pharmaceuticals, Inc. (TCON) EPS Estimated At $-0.19 Invest TribuneAnalysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
-
Analysts See $-0.44 EPS for Athenex, Inc. (ATNX); Premier Asset Managment Trimmed By $6.15 Million Its Intercontinental Exchange In (ICE) Position - The InvestReporter
Posted: August 1st, 2019, 12:21pm GMT
Analysts See $-0.44 EPS for Athenex, Inc. (ATNX); Premier Asset Managment Trimmed By $6.15 Million Its Intercontinental Exchange In (ICE) Position The InvestReporterAnalysts expect Athenex, Inc. (NASDAQ:ATNX) to report $-0.44 EPS on August, 13.They anticipate $0.14 EPS change or 24.14% from last quarter's $-0.58 EPS.
-
Angiosarcomas Treatment Market: Growth Analysis, Trends and Scope till 2024 - Financial Planning
Posted: August 1st, 2019, 8:42am GMT
Angiosarcomas Treatment Market: Growth Analysis, Trends and Scope till 2024 Financial PlanningRare and clinically highly variable, Sarcoma is a type of cancer that originates from mesenchymal cells transformation. Sarcoma defines as the major tumors, ...
-
TRACON Pharmaceuticals, Inc. (TCON) EPS Estimated At $-0.19 - Invest Tribune
Posted: August 1st, 2019, 4:25am GMT
TRACON Pharmaceuticals, Inc. (TCON) EPS Estimated At $-0.19 Invest TribuneAnalysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
-
DelMar Pharmaceuticals Inc. (DMPI)'s Financial Results Comparing With TRACON Pharmaceuticals Inc. (NASDAQ:TCON) - Stocks Beat
Posted: July 31st, 2019, 7:53pm GMT
DelMar Pharmaceuticals Inc. (DMPI)'s Financial Results Comparing With TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Stocks BeatDelMar Pharmaceuticals Inc. (NASDAQ:DMPI) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) compete against each other in the Biotechnology sector.
-
EPS for Athenex, Inc. (ATNX) Expected At $-0.44; Broadfin Capital Trimmed By $780,800 Its Intersect Ent (XENT) Position - The NBO News
Posted: July 31st, 2019, 3:39pm GMT
EPS for Athenex, Inc. (ATNX) Expected At $-0.44; Broadfin Capital Trimmed By $780,800 Its Intersect Ent (XENT) Position The NBO NewsBroadfin Capital Llc decreased Intersect Ent Inc (XENT) stake by 8.48% reported in 2019Q1 SEC filing. Broadfin Capital Llc sold 24,400 shares as Intersect Ent ...
-
Understanding sarcoma, one of the rarest cancers - Baylor College of Medicine News
Posted: July 31st, 2019, 12:23pm GMT
Understanding sarcoma, one of the rarest cancers Baylor College of Medicine NewsOncologist Dr. Daniel Wang discusses sarcoma, the rare “forgotten cancer” that impacts thousands of Americans every year.
-
Orphan Drugs Market Analysis Focusing on Top Key Players – AbbVie Inc., Aegerion Pharmaceuticals Inc., Bristol-Myers Squibb Company, Celgene Corporation - Hitech News Daily.
Posted: July 31st, 2019, 8:06am GMT
Orphan Drugs Market Analysis Focusing on Top Key Players – AbbVie Inc., Aegerion Pharmaceuticals Inc., Bristol-Myers Squibb Company, Celgene Corporation Hitech News Daily.According to a new report published by Allied Market Research, titled, "Orphan Drugs Market by Disease Type and Indication: Global Opportunity Analysis and ...
-
Angiosarcomas Treatment Market to Witness a Pronounce Growth by 2026 - Oak Tribune
Posted: July 31st, 2019, 3:05am GMT
Angiosarcomas Treatment Market to Witness a Pronounce Growth by 2026 Oak TribuneAngiosarcomas Treatment Market Report 2018 look into the study is an exceptionally tenacious examination on aggressive scene investigation, prime makers, ...
-
TRACON Pharmaceuticals, Inc. (TCON) EPS Estimated At $-0.19 - The Altcoin Mercury
Posted: July 31st, 2019, 2:34am GMT
TRACON Pharmaceuticals, Inc. (TCON) EPS Estimated At $-0.19 The Altcoin MercuryAnalysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
-
Y-mAbs Therapeutics, Inc. (YMAB) Analysts See $-0.48 EPS; Athenex (ATNX) SI Decreased By 2.6% - The InvestReporter
Posted: July 31st, 2019, 1:21am GMT
Y-mAbs Therapeutics, Inc. (YMAB) Analysts See $-0.48 EPS; Athenex (ATNX) SI Decreased By 2.6% The InvestReporterAnalysts expect Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) to report $-0.48 EPS on August, 9.After having $-0.47 EPS previously, Y-mAbs Therapeutics, Inc.'s ...
-
TRACON Pharmaceuticals, Inc. (TCON) on Focus After Trading At 52-Week Lows - Invest Tribune
Posted: July 30th, 2019, 1:52pm GMT
TRACON Pharmaceuticals, Inc. (TCON) on Focus After Trading At 52-Week Lows Invest TribuneThe stock of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) hit a new 52-week low and has $0.46 target or 5.00 % below today's $0.49 share price.
-
What Next for TRACON Pharmaceuticals, Inc. (TCON) Stock After Achieving 1 Year Low? - The MAK Daily
Posted: July 30th, 2019, 1:31pm GMT
What Next for TRACON Pharmaceuticals, Inc. (TCON) Stock After Achieving 1 Year Low? The MAK DailyThe stock of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) hit a new 52-week low and has $0.46 target or 5.00 % below today's $0.49 share price.
-
Analysts See $-0.44 EPS for Athenex, Inc. (ATNX); Harvest Capital Strategies Has Lowered Zoetis (ZTS) Stake - The InvestReporter
Posted: July 30th, 2019, 1:19pm GMT
Analysts See $-0.44 EPS for Athenex, Inc. (ATNX); Harvest Capital Strategies Has Lowered Zoetis (ZTS) Stake The InvestReporterAnalysts expect Athenex, Inc. (NASDAQ:ATNX) to report $-0.44 EPS on August, 13.They anticipate $0.14 EPS change or 24.14% from last quarter's $-0.58 EPS.
-
EPS for TRACON Pharmaceuticals, Inc. (TCON) Expected At $-0.19 - FinanceRecorder
Posted: July 30th, 2019, 1:33am GMT
EPS for TRACON Pharmaceuticals, Inc. (TCON) Expected At $-0.19 FinanceRecorderAnalysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
-
Ablation saves cancer patient's kidney - WNDU-TV
Posted: July 29th, 2019, 7:38pm GMT
Ablation saves cancer patient's kidney WNDU-TVKidney cancer is one of the Top 10 most common cancers and often leads to surgical removal of that organ.
-
What's Ahead for TRACON Pharmaceuticals, Inc. (TCON) After Achieving All-Time Low? - The MAK Daily
Posted: July 29th, 2019, 6:53pm GMT
What's Ahead for TRACON Pharmaceuticals, Inc. (TCON) After Achieving All-Time Low? The MAK DailyThe stock of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) reached all time low today, Jul, 29 and still has $0.48 target or 4.00 % below today's $0.50 share.
-
$-0.44 EPS Expected for Athenex, Inc. (ATNX); Cypress Funds Trimmed Its Xpo Logistics (XPO) Holding - CryptoCoinsTribune
Posted: July 29th, 2019, 5:12pm GMT
$-0.44 EPS Expected for Athenex, Inc. (ATNX); Cypress Funds Trimmed Its Xpo Logistics (XPO) Holding CryptoCoinsTribuneAnalysts expect Athenex, Inc. (NASDAQ:ATNX) to report $-0.44 EPS on August, 13.They anticipate $0.14 EPS change or 24.14% from last quarter's $-0.58 EPS.
-
TRACON Pharmaceuticals, Inc. (TCON) Analysts See $-0.19 EPS - The MAK Daily
Posted: July 29th, 2019, 1:44am GMT
TRACON Pharmaceuticals, Inc. (TCON) Analysts See $-0.19 EPS The MAK DailyAnalysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
-
Angiosarcomas Treatment Market: Business Opportunities, Current Trends, Market Challenges in 2026 - Forex Tribune
Posted: July 29th, 2019, 11:25pm GMT
Angiosarcomas Treatment Market: Business Opportunities, Current Trends, Market Challenges in 2026 Forex TribuneThe Angiosarcomas Treatment Market reports aims to convey a reasonable understanding of the business which has been analyzed by using primary and ...
-
$-0.44 EPS Expected for Athenex, Inc. (ATNX); Bb&T Securities Decreased Lilly Eli & Co (LLY) Stake By $378228 - The InvestReporter
Posted: July 28th, 2019, 6:10pm GMT
$-0.44 EPS Expected for Athenex, Inc. (ATNX); Bb&T Securities Decreased Lilly Eli & Co (LLY) Stake By $378228 The InvestReporterAnalysts expect Athenex, Inc. (NASDAQ:ATNX) to report $-0.44 EPS on August, 13.They anticipate $0.14 EPS change or 24.14% from last quarter's $-0.58 EPS.
-
TRACON Pharmaceuticals, Inc. (TCON) Analysts See $-0.19 EPS - The MAK Daily
Posted: July 28th, 2019, 3:22am GMT
TRACON Pharmaceuticals, Inc. (TCON) Analysts See $-0.19 EPS The MAK DailyAnalysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
-
Zacks: Brokerages Anticipate TRACON Pharmaceuticals Inc (NASDAQ:TCON) to Post -$0.19 EPS - Mayfield Recorder
Posted: July 26th, 2019, 11:45am GMT
Zacks: Brokerages Anticipate TRACON Pharmaceuticals Inc (NASDAQ:TCON) to Post -$0.19 EPS Mayfield RecorderWall Street analysts expect that TRACON Pharmaceuticals Inc (NASDAQ:TCON) will announce earnings per share (EPS) of ($0.19) for the current quarter, Zacks ...
-
Zacks: Analysts Anticipate TRACON Pharmaceuticals Inc (NASDAQ:TCON) Will Announce Earnings of -$0.19 Per Share - Slater Sentinel
Posted: July 26th, 2019, 11:42am GMT
Zacks: Analysts Anticipate TRACON Pharmaceuticals Inc (NASDAQ:TCON) Will Announce Earnings of -$0.19 Per Share Slater SentinelBrokerages forecast that TRACON Pharmaceuticals Inc (NASDAQ:TCON) will post ($0.19) earnings per share (EPS) for the current fiscal quarter, according to ...
-
TRACON Pharmaceuticals, Inc. (TCON) EPS Estimated At $-0.19 - The MAK Daily
Posted: July 26th, 2019, 10:29am GMT
TRACON Pharmaceuticals, Inc. (TCON) EPS Estimated At $-0.19 The MAK DailyAnalysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.19 EPS on August, 14.They anticipate $0.14 EPS change or 42.42 % from last ...
-
Booms and Busts in Angiosarcomas Treatment Market; Dynamics Trends Over The Time Discussed 2018-2026 - TechZiffy
Posted: July 26th, 2019, 5:09am GMT
Booms and Busts in Angiosarcomas Treatment Market; Dynamics Trends Over The Time Discussed 2018-2026 TechZiffyAngiosarcoma is a rare cancer of the inner lining of blood vessels, which occur in any area of the body, including the skin, breast, liver, spleen, and deep tissue ...
-
Comparing of TRACON Pharmaceuticals Inc. (TCON) and Osmotica Pharmaceuticals plc (NASDAQ:OSMT) - Stocks Beat
Posted: July 26th, 2019, 11:56pm GMT
Comparing of TRACON Pharmaceuticals Inc. (TCON) and Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Stocks BeatTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Osmotica Pharmaceuticals plc (NASDAQ:OSMT) compete with each other in the Biotechnology sector.
-
Comparing of TRACON Pharmaceuticals Inc. (TCON) and Midatech Pharma Plc (NASDAQ:MTP) - The InvestReporter
Posted: July 26th, 2019, 11:21pm GMT
Comparing of TRACON Pharmaceuticals Inc. (TCON) and Midatech Pharma Plc (NASDAQ:MTP) The InvestReporterTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Midatech Pharma Plc (NASDAQ:MTP), both competing one another are Biotechnology companies. We will ...
-
Leap Therapeutics Inc. (LPTX) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Comparing side by side - The InvestReporter
Posted: July 25th, 2019, 9:53am GMT
Leap Therapeutics Inc. (LPTX) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Comparing side by side The InvestReporterBoth Leap Therapeutics Inc. (NASDAQ:LPTX) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) are each other's competitor in the Biotechnology industry.
-
Angiosarcomas Treatment Market 2018: Industry Demand, Size, Share, Insight And Forecast 2026 | Coherent Market Insights - Coherent Magazine
Posted: July 25th, 2019, 4:00am GMT
Angiosarcomas Treatment Market 2018: Industry Demand, Size, Share, Insight And Forecast 2026 | Coherent Market Insights Coherent MagazineCoherent Market Insights recently published a detailed study of 'Angiosarcomas Treatment' Market covering interesting aspects of market with supporting ...
-
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Coherus BioSciences Inc. (NASDAQ:CHRS)'s results - The InvestReporter
Posted: July 25th, 2019, 2:07am GMT
Reviewing TRACON Pharmaceuticals Inc. (TCON)'s and Coherus BioSciences Inc. (NASDAQ:CHRS)'s results The InvestReporterTRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Coherus BioSciences Inc. (NASDAQ:CHRS) compete with each other in the Biotechnology sector. We will ...
-
TRACON Pharmaceuticals Inc. (TCON) and Adaptimmune Therapeutics plc (NASDAQ:ADAP) Comparing side by side - The InvestReporter
Posted: July 25th, 2019, 11:21pm GMT
TRACON Pharmaceuticals Inc. (TCON) and Adaptimmune Therapeutics plc (NASDAQ:ADAP) Comparing side by side The InvestReporterThis is a contrast between TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Adaptimmune Therapeutics plc (NASDAQ:ADAP) based on their analyst ...
-
What's Ahead for Tracon Pharmaceuticals Inc (NASDAQ:TCON) After More Shorted Shares? - The MAK Daily
Posted: July 24th, 2019, 5:31pm GMT
What's Ahead for Tracon Pharmaceuticals Inc (NASDAQ:TCON) After More Shorted Shares? The MAK DailyThe stock of Tracon Pharmaceuticals Inc (NASDAQ:TCON) registered an increase of 73.68% in short interest. TCON's total short interest was 430200 shares in.
-
TRACON Pharmaceuticals (NASDAQ:TCON) Trading Down 3.6% - Riverton Roll
Posted: July 24th, 2019, 12:06pm GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Trading Down 3.6% Riverton RollTRACON Pharmaceuticals Inc (NASDAQ:TCON) fell 3.6% during trading on Monday . The stock traded as low as $0.53 and last traded at $0.54, 2000 shares ...
-
Angiosarcoma Market Shares, Strategies and Forecast Worldwide, 2018 to 2025 - Crypto News Today
Posted: July 24th, 2019, 8:29am GMT
Angiosarcoma Market Shares, Strategies and Forecast Worldwide, 2018 to 2025 Crypto News TodayThe Angiosarcoma market is valued at USD XX million in 2018 and is expected to reach USD XX million by the end of 2026, growing at a CAGR of XX% ...
-
TRACON Pharmaceuticals Inc. (TCON) and Magenta Therapeutics Inc. (NASDAQ:MGTA) Comparing side by side - Stocks Beat
Posted: July 23rd, 2019, 9:59pm GMT
TRACON Pharmaceuticals Inc. (TCON) and Magenta Therapeutics Inc. (NASDAQ:MGTA) Comparing side by side Stocks BeatAs Biotechnology businesses, TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Magenta Therapeutics Inc. (NASDAQ:MGTA), are affected by contrast.
-
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Expected to Announce Earnings of -$0.19 Per Share - Mayfield Recorder
Posted: July 23rd, 2019, 8:35pm GMT
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Expected to Announce Earnings of -$0.19 Per Share Mayfield RecorderAnalysts expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to report earnings per share (EPS) of ($0.19) for the current fiscal quarter, Zacks Investment ...
-
Form S-3ASR Athenex, Inc. - StreetInsider.com
Posted: July 23rd, 2019, 6:53pm GMT
Form S-3ASR Athenex, Inc. StreetInsider.comThis prospectus relates to the offer and resale by the selling stockholders identified herein of up to 10,000,000 shares of our common stock, par value $0.001 per ...
-
Cooking Classes Help Cancer Survivors, Low-Income Families Stay Healthy - KERA News
Posted: July 23rd, 2019, 12:44pm GMT
Cooking Classes Help Cancer Survivors, Low-Income Families Stay Healthy KERA NewsGood nutrition is essential to staying healthy, but pulling it off on a tight budget — or when you're sick — can be tough. And that's when it's even more.
-
Athenex, Inc. (ATNX) Analysts See $-0.44 EPS; Aristotle Capital Boston Has Trimmed Nasdaq (NDAQ) Stake - The InvestReporter
Posted: July 23rd, 2019, 10:22am GMT
Athenex, Inc. (ATNX) Analysts See $-0.44 EPS; Aristotle Capital Boston Has Trimmed Nasdaq (NDAQ) Stake The InvestReporterAnalysts expect Athenex, Inc. (NASDAQ:ATNX) to report $-0.44 EPS on August, 13.They anticipate $0.14 EPS change or 24.14% from last quarter's $-0.58 EPS.
-
TRACON Pharmaceuticals (NASDAQ:TCON) Stock Price Down 3.6% - Mayfield Recorder
Posted: July 22nd, 2019, 4:55pm GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Stock Price Down 3.6% Mayfield RecorderShares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) were down 3.6% during trading on Monday . The stock traded as low as $0.53 and last traded at ...
-
TRACON Pharmaceuticals (NASDAQ:TCON) Stock Price Down 3.6% - Trent Times
Posted: July 22nd, 2019, 4:54pm GMT
TRACON Pharmaceuticals (NASDAQ:TCON) Stock Price Down 3.6% Trent TimesTRACON Pharmaceuticals Inc (NASDAQ:TCON)'s share price was down 3.6% during mid-day trading on Monday . The company traded as low as $0.53 and ...
-
CCYSL's Dubuc announced as FCC's finalist for Community MVP - FC Cincinnati
Posted: July 22nd, 2019, 2:30pm GMT
CCYSL's Dubuc announced as FCC's finalist for Community MVP FC CincinnatiCINCINNATI – Major League Soccer has announced the finalists for the 2019 MLS WORKS Community MVP Contest presented by Wells Fargo, which ...
-
Soft Tissue Sarcoma Treatment Market Size Incredible Possibilities and Growth Analysis and Forecast To 2026 - Financial Planning
Posted: July 22nd, 2019, 12:09pm GMT
Soft Tissue Sarcoma Treatment Market Size Incredible Possibilities and Growth Analysis and Forecast To 2026 Financial PlanningSarcoma are the type of cancer that develops from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. It occurs in the blood vessels, ...
-
Death Rates in Melanoma Fell Markedly Following the Proliferation of New Types of Therapies - Dermatology Advisor
Posted: July 22nd, 2019, 12:00pm GMT
Death Rates in Melanoma Fell Markedly Following the Proliferation of New Types of Therapies Dermatology AdvisorPatients are now able to get immunotherapies and targeted therapies at their local clinics, rather than having to travel to academic medical centers.
-
Analysts See $1.06 EPS for The Procter & Gamble Company (PG); Athenex (ATNX) Shorts Down By 2.6% - The InvestReporter
Posted: July 22nd, 2019, 9:27am GMT
Analysts See $1.06 EPS for The Procter & Gamble Company (PG); Athenex (ATNX) Shorts Down By 2.6% The InvestReporterAnalysts expect The Procter & Gamble Company (NYSE:PG) to report $1.06 EPS on July, 30.They anticipate $0.12 EPS change or 12.77% from last quarter's ...